EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting neddylation in cancer: molecular mechanisms, translational advances, and therapeutic challenges

Xin Tian, Xinghan Li, Dequan Liu, Ying Min, Yang Hu

Frontiers in Pharmacology · 29.10.2026 · 17

DOI: 10.3389/fphar.2026.1936781 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.10.2026. Verfasst von Xin Tian und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stomatology, General Hospital of Northern Theater Command, Shenyang, China. Die Arbeit nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neddylation is a ubiquitin-like post-translational modification that regulates cullin–RING ligases and selected non-cullin substrates involved in cell-cycle progression, DNA replication licensing, DNA-damage repair, apoptosis, hypoxic signaling, inflammatory responses, epithelial–mesenchymal transition, metabolic adaptation, and immune regulation. Many tumors rely on aberrant neddylation-dependent protein turnover to sustain proliferation, survival, metastatic plasticity, and therapeutic resistance, making this pathway a compelling anticancer target. This review outlines the molecular architecture of the NEDD8 cascade, encompassing NEDD8 activation, E2-mediated conjugation, E3/co-E3-facilitated ligation, deneddylation, and the central role of cullin–RING ligases as oncogenic effectors. It also examines the principal classes of neddylation-pathway inhibitors, including the first-in-class NEDD8-activating enzyme inhibitor MLN4924, newer NAE inhibitors such as TAS4464, emerging UBE2M- and UBE2F-directed approaches, DCN1/DCUN1-targeted inhibitors, and natural product-derived or other experimental compounds. Preclinical evidence across hematologic malignancies, gastrointestinal and genitourinary cancers, thoracic and head-and-neck tumors, brain tumors, and pediatric cancers indicates that neddylation inhibition can suppress tumor growth and enhance responses to chemotherapy, radiotherapy, apoptosis-targeted agents, proteasome inhibition, autophagy modulation, and immunotherapy. Nevertheless, clinical translation remains constrained by inadequate patient selection, context-dependent substrate accumulation, adaptive resistance, complex immune effects, and limited therapeutic windows. Future development should therefore move beyond empirical pan-pathway inhibition toward biomarker-guided, tumor-context-specific precision strategies integrating selective E1, E2, and E3 inhibitors, rational combination regimens, pharmacodynamic monitoring, resistance profiling, immune-state assessment, and tumor-targeted delivery systems.

Schlagwörter

Stichwörter der Autor:innen

Nedd8cancer therapycullin-RING ligasesneddylationpevonedistat

Autor:innen und Institutionen

  • Department of Stomatology, General Hospital of Northern Theater Command, Shenyang, China.
  • Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.

Zitieren

APA

Tian, X., Li, X., Liu, D., Min, Y., & Hu, Y. (2026). Targeting neddylation in cancer: molecular mechanisms, translational advances, and therapeutic challenges. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1936781

Vancouver

Tian X, Li X, Liu D, Min Y, Hu Y. Targeting neddylation in cancer: molecular mechanisms, translational advances, and therapeutic challenges. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1936781

BibTeX
@article{Tian2026,
  author = {Tian, Xin and Li, Xinghan and Liu, Dequan and Min, Ying and Hu, Yang},
  title = {Targeting neddylation in cancer: molecular mechanisms, translational advances, and therapeutic challenges},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1936781}
}
Kostenlos starten →